Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 2/20 | 0.32 |
| ▸ | CA2 | P00918 | 2/20 | 0.32 |
| ▸ | CA9 | Q16790 | 2/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA3 | P07451 | 1/20 | 0.32 |
| ▸ | CA4 | P22748 | 1/20 | 0.32 |
| ▸ | CA6 | P23280 | 1/20 | 0.32 |
| ▸ | CA5A | P35218 | 1/20 | 0.32 |
| ▸ | CA7 | P43166 | 1/20 | 0.32 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.32 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6365213 | 0.93 | ALDH1A1 (0.36) | ALDH1A1HSD17B10TDP1CYP3A4MAPK1 | |
| P-Chlorobenzenesulfonamide SCHEMBL6670303 | 0.77 | CA2 (0.54) | TDP1CA1CA2CA9CA12 | |
| SCHEMBL8641991 | 0.76 | ALDH1A1 (0.42) | ALDH1A1HSD17B10TDP1 | |
| SCHEMBL8638466 | 0.73 | ALDH1A1 (0.36) | ALDH1A1HSD17B10TDP1 | |
| 1,4-Dichlorobenzene SCHEMBL2043383 | 0.72 | — | — | |
| SCHEMBL14026730 | 0.69 | ALDH1A1 (0.32) | ALDH1A1HSD17B10TDP1 | |
| SCHEMBL6365575 | 0.69 | — | — | |
| SCHEMBL184464 | 0.67 | TSHR (0.47) | ALDH1A1HSD17B10TDP1CYP3A4MAPK1 | |
| SCHEMBL67558 | 0.67 | ALDH1A1 (0.65) | ALDH1A1HSD17B10TDP1CYP3A4MAPK1 | |
| SCHEMBL20241140 | 0.65 | TSHR (0.44) | ALDH1A1HSD17B10TDP1CYP3A4MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2408757-B1 | A NOVEL ALPHA-(N-SULFONAMIDO) ACETAMIDE COMPOUND INCORPORATING DEUTERIUM AS INHIBITOR OF BETA AMYLOID PEPTIDE PRODUCTION | BRISTOL MYERS SQUIBB CO (US) | 2014-06-25 | — | — | EP | disclosed |
| EP-2408757-A1 | NOVEL ALPHA-(N-SULFONAMIDO)ACETAMIDE COMPOUNDS INCORPORATING DEUTERIUM AS INHIBITORS OF BETA AMYLOID PEPTIDE PRODUCTION A NOVEL ALPHA-(N-SULFONAMIDO) ACETAMIDE COMPOUND INCORPORATING DEUTERIUM AS INHIBITOR OF BETA AMYLOID PEPTIDE PRODUCTION | Bristol-Myers Squibb Company (US) | 2012-01-25 | — | — | EP | disclosed |
| US-8044077-B2 | Alpha-(N-sulfonamido)acetamide compounds incorporating deuterium as inhibitors of beta amyloid peptide production | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-10-25 | — | — | US | disclosed |
| US-20100240719-A1 | NOVEL ALPHA-(N-SULFONAMIDO)ACETAMIDE COMPOUNDS INCORPORATING DEUTERIUM AS INHIBITORS OF BETA AMYLOID PEPTIDE PRODUCTION | BRISTOL-MYERS SQUIBB COMPANY | 2010-09-23 | — | — | US | disclosed |
| WO-2010107984-A1 | NOVEL ALPHA-(N-SULFONAMIDO)ACETAMIDE COMPOUNDS INCORPORATING DEUTERIUM AS INHIBITORS OF BETA AMYLOID PEPTIDE PRODUCTION A NOVEL ALPHA-(N-SULFONAMIDO) ACETAMIDE COMPOUND INCORPORATING DEUTERIUM AS INHIBITOR OF BETA AMYLOID PEPTIDE PRODUCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-09-23 | — | — | WO | disclosed |
| EP-1456179-A1 | DEUTERATED SUBSTITUTED PYRAZOLYLBENZYLSULFONAMIDES AND MEDICAMENTS COMPRISING SAID COMPOUNDS | Turicum Drug Development AG (CH) | 2004-09-15 | — | — | EP | disclosed |
| WO-2003050091-A1 | DEUTERATED SUBSTITUTED PYRAZOLYLBENZYLSULFONAMIDES AND MEDICAMENTS COMPRISING SAID COMPOUNDS | TURICUM DRUG DEVELOPMENT AG (CH) | 2003-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240719-A1 | NOVEL ALPHA-(N-SULFONAMIDO)ACETAMIDE COMPOUNDS INCORPORATING DEUTERIUM AS INHIBITORS OF BETA AMYLOID PEPTIDE PRODUCTION | APP, BACE1, PSEN1 | ALDH1A1 2637/4885HSD17B10 2636/4885TDP1 232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.